Correction

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours (British Journal of Cancer, (2019), 120, 6, (612-620), 10.1038/s41416-019-0389-6)

César Serrano, Adrián Mariño-Enríquez, Derrick L. Tao, Julia Ketzer, Grant Eilers, Meijun Zhu, Channing Yu, Aristotle M. Mannan, Brian P. Rubin, George D. Demetri, Chandrajit P. Raut, Ajia Presnell, Arin McKinley, Michael Heinrich, Jeffrey T. Czaplinski, Ewa Sicinska, Sebastian Bauer, Suzanne George, Jonathan A. Fletcher

    Research output: Contribution to journalComment/debate

    Abstract

    The additional information of this manuscript originally stated that the authors declare no competing interests. This statement was incorrect, and should instead have stated the following: M.C.H. has the following competing interests to declare: Equity interest at Molecular MD; Consulting at Molecular MD, Blueprint Medicines, Deciphera Pharmaceuticals; Expert Testimony at Novartis; Licensed patent with royalty payments at Novartis. The remaining authors have no competing interests to declare. The authors apologise for any convenience this may have caused.

    Original languageEnglish (US)
    JournalBritish Journal of Cancer
    DOIs
    StatePublished - Jan 1 2019

    Fingerprint

    Gastrointestinal Stromal Tumors
    Expert Testimony
    Protein-Tyrosine Kinases
    Mutation
    Pharmaceutical Preparations
    Neoplasms
    Imatinib Mesylate

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Cite this

    Correction : Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours (British Journal of Cancer, (2019), 120, 6, (612-620), 10.1038/s41416-019-0389-6). / Serrano, César; Mariño-Enríquez, Adrián; Tao, Derrick L.; Ketzer, Julia; Eilers, Grant; Zhu, Meijun; Yu, Channing; Mannan, Aristotle M.; Rubin, Brian P.; Demetri, George D.; Raut, Chandrajit P.; Presnell, Ajia; McKinley, Arin; Heinrich, Michael; Czaplinski, Jeffrey T.; Sicinska, Ewa; Bauer, Sebastian; George, Suzanne; Fletcher, Jonathan A.

    In: British Journal of Cancer, 01.01.2019.

    Research output: Contribution to journalComment/debate

    Serrano, C, Mariño-Enríquez, A, Tao, DL, Ketzer, J, Eilers, G, Zhu, M, Yu, C, Mannan, AM, Rubin, BP, Demetri, GD, Raut, CP, Presnell, A, McKinley, A, Heinrich, M, Czaplinski, JT, Sicinska, E, Bauer, S, George, S & Fletcher, JA 2019, 'Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours (British Journal of Cancer, (2019), 120, 6, (612-620), 10.1038/s41416-019-0389-6)', British Journal of Cancer. https://doi.org/10.1038/s41416-019-0487-5
    Serrano, César ; Mariño-Enríquez, Adrián ; Tao, Derrick L. ; Ketzer, Julia ; Eilers, Grant ; Zhu, Meijun ; Yu, Channing ; Mannan, Aristotle M. ; Rubin, Brian P. ; Demetri, George D. ; Raut, Chandrajit P. ; Presnell, Ajia ; McKinley, Arin ; Heinrich, Michael ; Czaplinski, Jeffrey T. ; Sicinska, Ewa ; Bauer, Sebastian ; George, Suzanne ; Fletcher, Jonathan A. / Correction : Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours (British Journal of Cancer, (2019), 120, 6, (612-620), 10.1038/s41416-019-0389-6). In: British Journal of Cancer. 2019.
    @article{9f3830cfd11749dfb82db50e94e0f89b,
    title = "Correction: Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours (British Journal of Cancer, (2019), 120, 6, (612-620), 10.1038/s41416-019-0389-6)",
    abstract = "The additional information of this manuscript originally stated that the authors declare no competing interests. This statement was incorrect, and should instead have stated the following: M.C.H. has the following competing interests to declare: Equity interest at Molecular MD; Consulting at Molecular MD, Blueprint Medicines, Deciphera Pharmaceuticals; Expert Testimony at Novartis; Licensed patent with royalty payments at Novartis. The remaining authors have no competing interests to declare. The authors apologise for any convenience this may have caused.",
    author = "C{\'e}sar Serrano and Adri{\'a}n Mari{\~n}o-Enr{\'i}quez and Tao, {Derrick L.} and Julia Ketzer and Grant Eilers and Meijun Zhu and Channing Yu and Mannan, {Aristotle M.} and Rubin, {Brian P.} and Demetri, {George D.} and Raut, {Chandrajit P.} and Ajia Presnell and Arin McKinley and Michael Heinrich and Czaplinski, {Jeffrey T.} and Ewa Sicinska and Sebastian Bauer and Suzanne George and Fletcher, {Jonathan A.}",
    year = "2019",
    month = "1",
    day = "1",
    doi = "10.1038/s41416-019-0487-5",
    language = "English (US)",
    journal = "British Journal of Cancer",
    issn = "0007-0920",
    publisher = "Nature Publishing Group",

    }

    TY - JOUR

    T1 - Correction

    T2 - Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours (British Journal of Cancer, (2019), 120, 6, (612-620), 10.1038/s41416-019-0389-6)

    AU - Serrano, César

    AU - Mariño-Enríquez, Adrián

    AU - Tao, Derrick L.

    AU - Ketzer, Julia

    AU - Eilers, Grant

    AU - Zhu, Meijun

    AU - Yu, Channing

    AU - Mannan, Aristotle M.

    AU - Rubin, Brian P.

    AU - Demetri, George D.

    AU - Raut, Chandrajit P.

    AU - Presnell, Ajia

    AU - McKinley, Arin

    AU - Heinrich, Michael

    AU - Czaplinski, Jeffrey T.

    AU - Sicinska, Ewa

    AU - Bauer, Sebastian

    AU - George, Suzanne

    AU - Fletcher, Jonathan A.

    PY - 2019/1/1

    Y1 - 2019/1/1

    N2 - The additional information of this manuscript originally stated that the authors declare no competing interests. This statement was incorrect, and should instead have stated the following: M.C.H. has the following competing interests to declare: Equity interest at Molecular MD; Consulting at Molecular MD, Blueprint Medicines, Deciphera Pharmaceuticals; Expert Testimony at Novartis; Licensed patent with royalty payments at Novartis. The remaining authors have no competing interests to declare. The authors apologise for any convenience this may have caused.

    AB - The additional information of this manuscript originally stated that the authors declare no competing interests. This statement was incorrect, and should instead have stated the following: M.C.H. has the following competing interests to declare: Equity interest at Molecular MD; Consulting at Molecular MD, Blueprint Medicines, Deciphera Pharmaceuticals; Expert Testimony at Novartis; Licensed patent with royalty payments at Novartis. The remaining authors have no competing interests to declare. The authors apologise for any convenience this may have caused.

    UR - http://www.scopus.com/inward/record.url?scp=85066155358&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85066155358&partnerID=8YFLogxK

    U2 - 10.1038/s41416-019-0487-5

    DO - 10.1038/s41416-019-0487-5

    M3 - Comment/debate

    JO - British Journal of Cancer

    JF - British Journal of Cancer

    SN - 0007-0920

    ER -